Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation
- 11 February 2011
- journal article
- Published by Wiley in Sociology of Health & Illness
- Vol. 33 (5) , 731-747
Abstract
Government regulators have increasingly accelerated new cancer drugs on to the market by granting them approval based on less clinical data supporting drug efficacy than permitted under standard regulations. With more lenient regulatory standards, pharmaceutical companies have keenly sought to develop cancer drugs. Focusing on the US, this article examines how the emergence and implementation of such accelerated approvals should be understood, particularly in relation to corporate bias and disease‐politics theories. Drawing on longitudinal and case study data analysis, it is argued that the emergence of accelerated approval regulations for cancer drugs should be regarded primarily as part of a deregulatory regime driven by the interests of the pharmaceutical industry in partnership with all major aspects of the state, rather than as a response to patient activism in the aftermath of AIDS. Furthermore, even in cases when some patients successfully demand accelerated marketing approval of cancer drugs, such approval by regulators, while in manufacturers’ interests, may not be in the interests of patients’ health because the political culture of the regulatory agency is reluctant to uphold its own techno‐regulatory standards of public‐health protection when that would challenge the agenda‐setting influence of manufacturers, including industry collaborations with patients and the medical profession.Keywords
This publication has 31 references indexed in Scilit:
- Partial Progress: Governing the Pharmaceutical Industry and the Nhs, 1948–2008Journal of Health Politics, Policy and Law, 2009
- Living DrugsScience as Culture, 2009
- Deficits, Expectations and Paradigms in British and American Drug Safety AssessmentsScience, Technology, & Human Values, 2007
- Change in the policy community of human genetics: a pragmatic approach to open governancePolicy & Politics, 2006
- A comparative analysis of drug safety withdrawals in the UK and the US (1971–1992): Implications for current regulatory thinking and policySocial Science & Medicine, 2005
- Exploring clinician uncertainty in the diagnosis and treatment of attention deficit hyperactivity disorderSociology of Health & Illness, 2005
- Surrogate Endpoints And FDA’s Accelerated Approval ProcessHealth Affairs, 2005
- Demand Grows for Early Access to Promising Cancer DrugsJNCI: Journal of the National Cancer Institute, 2002
- Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval?Social Science & Medicine, 1999
- Tranquillisers as a Social ProblemThe Sociological Review, 1988